Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of Your #1 4K television: Lucidity and Drenching Matter - 2April full moon 2026 dazzles as 'Pink Moon' lights up skies worldwide (photos)
- 3Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
- 4Muslim Brotherhood stole half a billion dollars in Gaza donations, Arab sources reveal
- 58 Espresso Bean Starting points All over the Planet
- 10 Demonstrated Systems to Develop Your Internet based Business
- San Francisco sues 10 companies that make ultraprocessed food
- Different Film Classification: What's Your Go-To for Amusement
- Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- Limited Rain Chances in Brazil Boost Coffee Prices
- Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
- Study casts doubt on potential for life on Jupiter's moon Europa
